Last updated on September 2018

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care


Brief description of study

This low interventional study, whose unique intervention will be to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, will assess if the cardiologist referral guided by NT-proBNP measurement in patients who are currently judged by PCPs as being stable, will lead to optimization of HF treatment, defined in adherence to treatment recommendations of the current European Society of Cardiology guidelines for the treatment of heart failure.

Detailed Study Description

In the majority of European countries, the primary management of chronic heart failure patients is performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies have shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides (BNP, NT-proBNP) is associated with increased risk of cardiovascular events in heart failure patients. The purpose of the present study is to assess if a referral of clinical stable chronic heart failure patients with reduced ventricular ejection fraction (EF < or = 40%) and NT-proBNP level > or = 600 pg/mL to a specialist (cardiologist) will lead to treatment optimization, defined as adherence to the treatment recommendations according to the European Society of Cardiology (ESC) guidelines. In addition, data obtained in this study will be used to describe demographic, clinical (including NT-proBNP levels) and treatment characteristics of CHF patients who are managed in the primary care setting across Europe..

Clinical Study Identifier: NCT02807857

Find a site near you

Start Over

Novartis Investigative Site

Buggenhout, Belgium, Belgium
  Connect »

Novartis Investigative Site

Ezemaal-Neerwinden, Belgium
  Connect »

Novartis Investigative Site

Hasselt, Belgium, Belgium
  Connect »

Novartis Investigative Site

Massemen, Belgium, Belgium
  Connect »

Novartis Investigative Site

Mont sur Marchienne, Belgium
  Connect »

Novartis Investigative Site

St-Genesius-Rode, Belgium
  Connect »

Novartis Investigative Site

Breteuil sur Seine, France
  Connect »

Novartis Investigative Site

Les Pennes Mirabeau, France
  Connect »

Novartis Investigative Site

Rosiers d'Egleton, France
  Connect »

Novartis Investigative Site

St orens de Gameville, France
  Connect »

Novartis Investigative Site

Balatonkeresztur, Hungary
  Connect »

Novartis Investigative Site

Grumello Del Monte, Italy
  Connect »

Novartis Investigative Site

Miasteczko Slaskie, Poland
  Connect »

Novartis Investigative Site

Leca da Palmeira, Portugal
  Connect »

Novartis Investigative Site

Kazan, Russian Federation
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Petrozavodsk, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

St.- Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Vladivostok, Russian Federation
  Connect »

Novartis Investigative Site

Yaroslavl, Russian Federation
  Connect »

Novartis Investigative Site

Pesnica pri Mariboru, Slovenia
  Connect »

Novartis Investigative Site

Slovenske Konjice, Slovenia
  Connect »

Novartis Investigative Site

El Parador de las Hortichiuela, Spain
  Connect »

Novartis Investigative Site

Breteuil Sur Seine, France
  Connect »

Novartis Investigative Site

El Parador De Las Hortichiuela, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.